Pharmaceuticals · Pharmaceuticals: Major · NSE: ACCPL · data 2026-10-30

Accretion Pharmaceuticals Ltd.

₹190.05+5.00% on 30 OctHealth: Strong 9.1/10

Jan 2026Low ₹63.05 · High ₹219+182.4%

In plain words

Price: 13.6% below its 52-week high of ₹220.

A description of the data, not a recommendation.

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹190.05

Market cap

₹201 cr

P/E

21.9

P/B

3.9

ROE

27.6%

ROCE

38.3%

Debt / equity

0.23

Dividend yield

0.00%

1-year return

234.9%

52-week high

₹220

52-week low

₹54.6

Operating margin

15.3%

Growth

Revenue (last 12 months)	₹90 cr
Net profit (last 12 months)	₹10 cr
Sales growth, 3 years (yearly)	45.0%
Profit growth, 3 years (yearly)	353.1%

Smart-money activity

5/100 · Weak over the last ~60 sessions

Delivery vs usual 0/30: No stored daily delivery history for this stock (0 points).
Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
Promoter pledges 5/5: No promoter pledge filings in 90 days.

A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.

Common questions

Is Accretion Pharmaceuticals Ltd. debt-free?

Its latest reported debt-to-equity ratio is 0.23.

What is Accretion Pharmaceuticals Ltd.'s P/E ratio?

About 21.9, based on the last 12 months' earnings and a price of ₹190.05 (data 2026-10-30).

What is the 52-week high and low of Accretion Pharmaceuticals Ltd.?

The 52-week high is ₹220 and the 52-week low is ₹54.6.

Similar companies

Ambalal Sarabhai Enterprises Limited (AMBALALSA) · Nectar Lifesciences Ltd. (NECLIFE) · Brooks Laboratories Limited (BROOKS) · Medico Remedies Ltd. (MEDICO) · Curis Lifesciences Limited (CURIS)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open ACCPL in NSE Scanner →